Single Cell Analysis Identifies the miRNA Expression Profile of a Subpopulation of Muscle Precursor Cells Unique to Humans With Type 2 Diabetes by Henriksen, Tora I. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Single Cell Analysis Identifies the miRNA Expression Profile of a Subpopulation of
Muscle Precursor Cells Unique to Humans With Type 2 Diabetes
Henriksen, Tora I.; Heywood, Sarah E; Hansen, Ninna S; Pedersen, Bente K; Scheele,
Camilla C; Nielsen, Søren
Published in:
Frontiers in Physiology
DOI:
10.3389/fphys.2018.00883
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Henriksen, T. I., Heywood, S. E., Hansen, N. S., Pedersen, B. K., Scheele, C. C., & Nielsen, S. (2018). Single
Cell Analysis Identifies the miRNA Expression Profile of a Subpopulation of Muscle Precursor Cells Unique to
Humans With Type 2 Diabetes. Frontiers in Physiology, 9, 1-13. [883]. https://doi.org/10.3389/fphys.2018.00883
Download date: 03. Feb. 2020
fphys-09-00883 July 10, 2018 Time: 16:37 # 1
ORIGINAL RESEARCH
published: 11 July 2018
doi: 10.3389/fphys.2018.00883
Edited by:
Giuseppe D’Antona,
University of Pavia, Italy
Reviewed by:
Roberto Cannataro,
University of Calabria, Italy
Yuko Tanimura,
Aichi Toho University, Japan
*Correspondence:
Søren Nielsen
soren_nielsen@
inflammation-metabolism.dk
Specialty section:
This article was submitted to
Striated Muscle Physiology,
a section of the journal
Frontiers in Physiology
Received: 09 April 2018
Accepted: 19 June 2018
Published: 11 July 2018
Citation:
Henriksen TI, Heywood SE,
Hansen NS, Pedersen BK,
Scheele CC and Nielsen S (2018)
Single Cell Analysis Identifies
the miRNA Expression Profile of a
Subpopulation of Muscle Precursor
Cells Unique to Humans With Type 2
Diabetes. Front. Physiol. 9:883.
doi: 10.3389/fphys.2018.00883
Single Cell Analysis Identifies the
miRNA Expression Profile of a
Subpopulation of Muscle Precursor
Cells Unique to Humans With Type 2
Diabetes
Tora I. Henriksen1,2, Sarah E. Heywood1, Ninna S. Hansen1, Bente K. Pedersen1,
Camilla C. Scheele1,2 and Søren Nielsen1*
1 Centre for Inflammation and Metabolism and the Centre for Physical Activity Research, Rigshospitalet, University of
Copenhagen, Copenhagen, Denmark, 2 The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
MicroRNAs (miRNAs) take part in regulating central cellular processes such as
differentiation and metabolism. We have previously shown that muscle progenitor
cells derived from individuals with type 2 diabetes (T2DM) have a dysregulated
miRNA profile. We hypothesized that the T2DM muscle progenitor population is
heterogeneous in its miRNA expression and differs from the progenitor population
of healthy controls. MiRNA expression profiles of CD56+ muscle progenitor cells
from people with T2DM and from healthy controls were therefore investigated at a
single cell level. Single-cell analysis revealed three subpopulations expressing distinct
miRNA profiles: two subpopulations including both T2DM and healthy control muscle
precursors presented miRNA expression profiles mostly overlapping between groups.
A distinct third subpopulation consisted solely of cells from donors with T2DM and
showed enriched expression of miRNAs previously shown to be associated with
type 2 diabetes. Among the enriched miRNAs was miR-29, a regulator of GLUT4
mRNA expression. Interestingly, this subpopulation also revealed several miRNAs with
predicted targets in the PI3K/Akt pathway, not previously described in relation to T2DM
muscle dysfunction. We concluded that a subpopulation of T2DM muscle precursor
cells is severely dysregulated in terms of their miRNA expression, and accumulation of
this population might thus contribute to the dysfunctional muscular phenotype in type 2
diabetes.
Keywords: diabetes, human, microRNA, muscle, satellite cell, single-cell analysis, muscle stem cells
INTRODUCTION
Skeletal muscle is a major target for insulin-stimulated glucose uptake, and dysregulated muscle
metabolism is a hallmark of type 2 diabetes (T2DM) (Czech, 2017). MicroRNAs (miRNAs)
are short, non-coding RNAs that post-transcriptionally modulate gene expression (Lee et al.,
1993; Lim et al., 2005) and have been shown to regulate metabolism and insulin sensitivity
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(Frost and Olson, 2011; Trajkovski et al., 2011; Kornfeld et al.,
2013). Accordingly, multiple disease pathologies are associated
with aberrant miRNA expressions, including type 2 diabetes (He
et al., 2017).
Skeletal muscle expresses augmented levels of a number
of miRNAs (Sempere et al., 2004) which regulate critical
muscle cell processes, such as differentiation and mitochondrial
biogenesis (Chen et al., 2006; Yamamoto et al., 2012).
Considering the central role of muscle dysfunction in T2DM,
it is not surprising that skeletal muscle of patients with
T2DM presents a dysregulated miRNA expression profile
(Gallagher et al., 2010; Bork-Jensen et al., 2015). In line
with this, we recently showed that isolated muscle stem cells
from T2DM donors have a discordant miRNA expression
profile compared with cells from healthy controls, resulting
in impaired myogenesis (Henriksen et al., 2017). However,
out of approximately 1000 analyzed miRNAs, we only found
5 miRNAs to be differentially expressed in the T2DM cells,
whereas the expression of a number of miRNAs were just
below the threshold for statistical significance when corrected
for multiple testing (Henriksen et al., 2017). In addition,
several of the borderline significant miRNAs could be localized
to genomic clusters also hosting the five significantly altered
transcripts. A heterogeneous cell population could provide one
explanation for the observed blunted disease phenotype, since
measuring an average based on a whole cell population can
mask relevant expression patterns in underlying subpopulations
of cells (Altschuler and Wu, 2010). Moreover, subpopulation
trends may disappear or appear reversed when combined into
an ensemble measurement, as explained by Simpson’s Paradox
(Simpson, 1951).
Skeletal muscle progenitor cells (satellite cells) represent
just one player in a heterogeneous stem cell niche that
also includes fibroblasts (Agley et al., 2015). Besides the
interaction between the two cells types (Mackey et al., 2017),
the stem cell microenvironments are also affected by other
factors such as hormones, metabolites and biomechanical forces
(Gattazzo et al., 2014). All of these are factors that are
altered in a type 2 diabetic state and can thereby modulate
the stem cell phenotype (Park et al., 2006; Lewitt et al.,
2014; Molnos et al., 2017). It is therefore likely that muscle
progenitor cells represent a heterogeneous cell group with
distinct cellular subpopulations, and likewise may encompass
discreet myoblast subpopulations with similarly diverse miRNA
expression profiles.
Our previous finding that muscle progenitor cells from T2DM
donors only express a low number of significantly differently
expressed miRNAs compared with healthy donors might thus
be due to averaging miRNA expressions in a heterogeneous
cell population. With the present study, we therefore address
this issue at a single-cell level by sorting individual CD56+
muscle progenitor cells from people with T2DM and healthy
control subjects, and analyzing miRNAs previously reported to
be borderline significantly expressed between the two groups
(Henriksen et al., 2017). We hypothesize that human muscle
progenitor cells have cellular subpopulations with distinct
miRNA expression profiles, and that muscle progenitor cells
from T2DM donors have distinct miRNA expression profiles
compared with healthy donors.
RESEARCH DESIGN AND METHODS
Human Subjects
Cell cultures were obtained from male donors (Table 1) included
in a previously described study (Pedersen et al., 2012). A total
of 3 of the 5 diabetic donors were taking a combination of
Simvastatin and either Metformin or Acetylsalicylic acid; one
donor was taking Centyl (a diuretic) and an ACE-inhibitor in
addition to Simvastatin and Metformin. To minimize the effect
of different treatments participants with type 2 diabetes were not
allowed taking any antidiabetic medication for one week before
meeting at the hospital. None of the diabetic donors received
insulin as medication. All participants gave written informed
consent before inclusion. The study was performed according
to the Declaration of Helsinki and approved by The Regional
Committee on Biomedical Research Ethics in Denmark (KF
01-141/04).
Materials
F10 nutrient mixture (HAM), Dulbecco’s modified Eagle’s
medium (DMEM), fetal bovine serum (FBS), horse serum
(HS), penicillin/streptomycin (P/S), and Fungizone antimycotic
(FZ) were obtained from Invitrogen (Taastrup, Denmark).
CD56-conjugated microbeads were from Miltenyi Biotec (Lund,
Sweden). C1TM System and C1 integrated fluidic circuits
(IFCs) were from Fluidigm (San Francisco, CA, United States).
LIVE/DEAD cell staining solution, ActinRed and NucBlue
ReadyProbes antibodies, and Megaplex PreAmp primers were
from Thermo Scientific (Taastrup, Denmark).
Microarray
As previously described (Henriksen et al., 2017), a miRCURY
LNA microRNA Array (sixth gen – hsa, mmu, and rno) (Exiqon,
Denmark) was utilized for global miRNA detection between
TABLE 1 | Clinical characteristics of muscle precursor cell donors.
Healthy (n = 5) T2DM (n = 5)
Age (years) 55.0 (50–59) 58 (52–66)
BMI (kg/m2) 23.8 ± 1.3 27.4 ± 0.9∗∗
Fasting glucose (mmol/L) 5.1 ± 0.6 9.4 ± 3.4∗
OGTT 2-h glucose (mmol/L) 5.5 ± 0.8 17.9 ± 6.3∗∗
Fasting insulin (pmol/L) 42.2 ± 11.6 61.4 ± 17.1
OGTT 2-h insulin (pmol/L) 305.8 ± 197.6 223 ± 161.9
HOMA-IR 1.6 ± 0.5 4.3 ± 1.9∗
VO2 max (L/min) 2.9 ± 0.7 2.4 ± 0.7
VO2 max (mL/min/kg) 35.9 ± 9.9 26.8 ± 6.4
Data are means ± SE. BMI = body mass index; OGTT = oral glucose tolerance
test. Glucose values are mmol/L, and insulin values are pmol/L. Differences
between groups were compared using Student’s unpaired t-test. ∗P < 0.05,
∗∗P < 0.001, ∗∗∗∗P < 0.0001.
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human muscle stem cells derived from T2DM subjects and
healthy controls during differentiation (GSE86069).
Human Muscle Satellite Cell Isolation
and Culture
Satellite cells were isolated from vastus lateralis muscle biopsies
as previously described (Green et al., 2011). After removal of
fat and connective tissue, the muscle biopsy was minced into
small pieces and digested in buffer containing 0.05% trypsin-
EDTA, 1 mg/ml collagenase IV and 10 mg/ml BSA for 5 min
at 37◦C. Subsequently, digestion solution containing liberated
muscle precursor cells was transferred to cold FBS to stop
trypsin activity. The solution was centrifuged at 800 g for 7 min.
The supernatant was removed and washed with F10/HAM. To
minimize fibroblast contamination, the cell suspension was pre-
plated in a culture plate for 3 h in growth medium containing
20% FBS, 1% PS, and 1% FZ in F10/HAM. The unattached
cells were seeded onto Matrigel coated culture flasks (0.01%
Matrigel in F10/HAM, 30 min at 37◦C) and cultured for
4 days in growth medium in a humidified incubator with
5% O2 and 5% CO2 at 37◦C. After 4 days of incubation,
cell culture medium was changed and then every second day
thereafter. All experiments were performed on myoblasts at
passage 1–2.
Immunomagnetic Sorting of CD56+ Cells
Cells were sorted for the cell surface marker CD56 using
immunomagnetic column sorting (MACS) to achieve pure
populations of muscle precursor cells, as described by Agley
et al. (2015). Cells grown to ∼50% confluency in a 10 cm
culture dish were incubated with Human CD56 primary antibody
conjugated magnetic microbeads (Miltenyi Biotec) at 4◦C for
30 min. CD56+myoblasts were filtered from the bulk population
using a magnetic cell separator (Miltenyi Biotec) according to the
manufacturer’s instructions (Miltenyi Biotec).
Single Cell miRNA Amplification
Single cell capture, specific reverse transcription of miRNAs, and
cDNA pre-amplification were performed using the Fluidigm R©
C1TM System. The cells were loaded in the C1TM Single-Cell
Preamp IFC, for cell size 10–17 µm (Fluidigm) according to the
manufacturer’s protocol (PN 100-6667). Pre-amplification was
performed using Megaplex PreAmp Pool A primers (Thermo
Scientific) and Single Cell PreAmp Mix (Ambion). Cells were
stained with a LIVE/DEAD fluorescent assay (Thermo Scientific)
to identify presence of living cells. All cell capture sites were
manually inspected on an EVOS FL fluorescent microscope
(Thermo Scientific); capture sites containing debris, multiple
or dead cells, or no cells were excluded from further analysis
(Figure 2C and Table 2).
RT-PCR
Targeted miRNA expression analysis was performed using a
gene expression Dynamic ArrayTM 48.48 IFC (PN 68000130)
on an MX IFC controller and the BioMark HD System for
real-time PCR (RT-PCR; Fluidigm). TaqMan miRNA primer
assays and TaqMan Universal PCR Master Mix, no AmpErase
UNG was used for the qPCR (Thermo Scientific). A total of
34 miRNAs were selected for analysis based on their relative
expression between healthy and T2DM groups in a previous
study (Henriksen et al., 2017); the included miRNAs are listed in
Table 3.
FACS
Isolated muscle precursor cells were propagated in growth
medium as described above until 70% confluence. Cells were
detached using TrypLETM Express, and subsequently washed
twice in FACS buffer [phosphate-buffered saline (PBS) containing
2% heat inactivated FBS]. Cells were stained with anti-
human CD56-APC, CD31-PE, and CD45-BV421 (all from BD
Bioscience) for 20 min and subsequently washed twice in
FACS buffer. Data was acquired using a FACS Fortessa (BD
Biosciences). For compensation, single stain was used with one
drop of negative control beads and anti-mouse IgG beads (BD
Biosciences). Data analysis was performed using FlowJo software
version 10.
Pathway Prediction and miRNA Target
Gene Analysis
The miRNA target pathway predictions were performed using
Diana miRPath software (Vlachos et al., 2012) based on
TargetScan analysis. Context score was set to 0.4, P-value was
set to 0.05, and conservative stats were applied. To visualize
miRNA-gene interactions the CytoScape app CyTargetLinker was
TABLE 2 | IFC cell capture rates.
Healthy T2DM Total
Donors 32a 40a 92a 21a 99a 129a 113a 7a 27a 48a Healthy T2DM
Captured 83 86 84 25 43 87 46 79 14 88 321 314
Live 56 62 70 19 37 74 36 64 14 72 244 260
No Capture 13 10 12 71 53 9 50 17 82 8 159 166
Dead 4 2 1 1 0 1 0 3 0 2 8 6
Debris 15 19 10 3 1 4 5 4 0 10 48 23
Multiple 8 3 3 2 5 8 5 8 0 4 21 25
Total 96 96 96 96 96 96 96 96 96 96 480 480
Individual quality control scoring of capture sites in single cell 96 capture site IFCs.
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TABLE 3 | Differentially expressed miRNA.
t-test (P-values) log2 fold change
miRNA T2DM vs.
T2DM group 2
Healthy vs.
T2DM group 2
Healthy
vs. T2DM
Healthy
vs. Mix
T2DM vs.
T2DM group 2
Healthy vs.
T2DM group 2
Healthy
vs. T2DM
Healthy
vs. Mix
miR-24 1,7E-59 2,7E-74 8,8E-06 1,8E-15 −5,5 −6,1 −0,7 2,7
miR-191 7,7E-38 2,7E-77 9,5E-01 7,4E-27 −7,0 −7,7 −0,8 3,6
miR-29c 7,2E-36 6,0E-38 7,5E-01 5,6E-08 −6,9 −6,9 0,0 3,6
miR-29b 6,0E-30 9,7E-34 5,5E-01 5,0E-01 −11,5 −12,8 −1,2 9,4
miR-210 2,1E-23 1,5E-25 6,0E-02 2,4E-04 −9,4 −8,4 0,9 5,6
miR-29a 2,1E-22 4,6E-56 1,7E-04 7,7E-22 −4,8 −5,2 −0,4 3,6
miR-17 6,7E-19 1,2E-37 5,7E-04 1,8E-32 −5,7 −5,4 0,3 6,1
miR-19b 3,8E-17 1,2E-24 7,8E-01 8,5E-14 −5,6 −5,8 −0,2 2,3
miR-27b 9,7E-17 2,8E-14 2,3E-01 8,7E-03 −6,3 −6,4 −0,1 15,1
miR-193b 2,2E-16 8,0E-19 2,9E-03 1,8E-05 −5,6 −5,9 −0,3 3,8
miR-199a-3p 1,8E-14 1,6E-13 1,6E-01 1,4E-08 −6,7 −7,0 −0,3 7,5
miR-138 8,3E-07 2,0E-07 4,8E-01 3,3E-03 −1,1 −1,4 −0,3 1,5
miR-30c 3,5E-05 2,4E-05 5,0E-01 1,5E-12 −4,9 −5,2 −0,3 6,1
miR-125b 3,6E-05 3,6E-05 8,6E-01 2,8E-13 −7,2 −7,3 −0,1 14,7
miR-365 1,7E-04 3,0E-04 6,7E-01 9,6E-05 −5,0 −5,6 −0,6 1,9
miR-214 4,1E-04 4,7E-04 2,7E-01 3,6E-06 −6,0 −6,1 −0,1 2,6
miR-20a 2,2E-03 3,5E-03 6,7E-01 3,1E-06 −5,3 −5,4 −0,2 7,7
miR-27a 1,4E-02 3,4E-02 9,0E-02 2,2E-07 −5,0 −4,6 0,4 2,7
miR-145 1,9E-02 2,2E-02 1,7E-03 3,4E-02 −8,5 −6,2 2,3 3,7
miR-106b 7,9E-02 5,6E-02 2,7E-01 1,7E-03 −3,7 −3,5 0,2 15,1
miR-195 1,0E-01 7,1E-02 6,2E-01 3,6E-04 −2,8 −3,1 −0,3 11,5
miR-30b 1,1E-01 2,5E-01 9,0E-01 8,1E-08 −4,8 −5,6 −0,8 2,8
miR-10a 1,2E-01 7,5E-02 7,0E-03 2,6E-01 −9,6 −7,6 2,0 11,7
miR-143 5,9E-01 3,8E-01 5,9E-02 1,3E-01 −4,3 −4,5 −0,3 12,3
miR-140-3p 6,2E-01 5,7E-01 3,0E-01 1,8E-01 −3,3 −3,4 −0,1 8,7
miR-708 9,6E-01 9,2E-01 8,3E-01 6,7E-04 −4,2 −4,1 0,1 2,9
Differences between groups were compared using Student’s unpaired t-test with Bonferroni’s correction for multiple testing. Significant inter-group differences are
highlighted in green.
used (Shannon et al., 2003; Kutmon et al., 2013). Regulatory
interaction networks comprising miRNA-target interactions were
obtained from http://projects.bigcat.unimaas.nl/cytargetlinker/
regins. Validated targets (miRTarBase) and predicted targets
(MicroCosm and TargetScan) were integrated and overlap
threshold was set to 1. The resulting interaction network
was crosschecked for genes within the PI3K/Akt signaling
pathway.
Statistical Analyses
The RT-qPCR data was pre-processed on the Biomark software
(Fluidigm). Threshold (0.1) and baseline were adjusted for
comparison across the IFC qPCR plates. A quality control score at
0.6 (QC feature in Biomark software) was defined as a successful
signal. All live cells expressing RNU48 were included in the
analysis. miRNA qPCR assays with an efficiency higher than 10%
were used as an inclusion criterion. All dead cells, multiple cells
and debris were filtered and excluded from the data. Relative
values were then calculated using the standard curve method.
Expression levels are presented per cell and not normalized
to a reference gene as when performing bulk qPCR analysis.
To identify differentially expressed miRNAs between groups, an
unpaired t-test was performed. P-values (0.05) were corrected
for multiple comparisons using the Bonferroni’s correction
approach. To visualize clustering of multivariate data, miRNA
qPCR data was log-transformed and uploaded to the web-based
bioinformatic tool ClustVis (Metsalu and Vilo, 2015). A principal
component analysis (PCA) plot (PC1: 28.9% and PC2: 6.7%)
was generated to identify unique clusters within the two groups.
After identification of clusters, data was classified in four unique
groups and a heat map (unsupervised clustering) was performed.
The method for clustering rows and columns was ‘average’ and a
Manhattan approach was used to visualize column distance.
RESULTS
A schematic overview of the study workflow is seen in
Figure 1A. A global ensemble miRNA analysis previously
performed in differentiating muscle precursor cells from
healthy and T2DM donors showed that a subset of miRNAs
tended to be differentially regulated in differentiating T2DM
muscle precursors (Henriksen et al., 2017). Unsupervised
clustering analysis of this data set revealed a tendency
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for group-based clustering, however, this varied considerably
between cells from individual donors (Figure 1B), suggesting
heterogeneity of miRNA expression within cells of each
group. We therefore hypothesized that the miRNA expression
of individual cells would vary between groups. To address
this hypothesis, we selected 34 miRNAs identified as either
significant or borderline significantly expressed between healthy
and T2DM groups (Henriksen et al., 2017) for single-cell
analysis in the present study. The miRNA included for
single-cell analysis are listed in Table 3 and the miRNA
assay detection rates in the present study are shown in
Figure 3A.
FIGURE 1 | (A) Schematic overview of study workflow. Muscle precursor cells included in the present study were isolated from healthy (n = 5) or T2DM (n = 5)
donors (donor characteristics are summarized in Table 1). Proliferating myoblasts expressing the myoblast marker CD56 were positively selected for further analysis.
Individual cells were isolated through use of single-cell microfluidics and assessed for their respective miRNA expression profiles. (B) Heat map of bulk miRNA
expression in healthy versus T2DM proliferating muscle precursors. This is a subset of data previously described (Henriksen et al., 2017).
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FIGURE 2 | (A) Flow cytometry analysis of healthy and T2DM muscle precursor cells. Representative histograms for positive (orange) and negative (red) cell subsets:
CD31 conjugated to PE; CD45 conjugated to BV421 and CD56 conjugated to APC. (B) Immunofluorescence images of cells from healthy (left panel) or T2DM
donors (right panel) stained for actin (red) or nucleus (blue). Scale bar indicates 400 µm. Representative images are shown. (C) Immunofluorescence images of IFC
capture sites containing single, live cell stained with Calcein-AM (left image; green) or multiple dead cells stained with ethidium-homodimer 1 (right image; red). Scale
bar indicates 400 µm.
Primary myoblasts from healthy or type 2 diabetic donors
were subjected to immunomagnetic column sorting to positively
select for CD56 as a marker of myogenic cells; clinical
characteristics of cell donors are shown in Table 1. We
subsequently performed FACS analysis of a subset of cells to
verify myogenic purity of cell cultures. The analyzed cells did
not express endothelial marker CD31 or hematopoietic marker
CD45, confirming the absence of endothelial and immune cells
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FIGURE 3 | (A) miRNA detection rates in healthy versus T2DM muscle precursor cells. miRNA detected to a higher degree in T2DM cells are highlighted in red;
miRNA detected to a higher degree in healthy cells are highlighted in green. (B) Principal component analysis of single-cell miRNA expression in the four defined
groups (Healthy, Mixed, T2DM group 1 and T2DM group 2). (C) A heat map including the miRNA expression for all four groups defined by PCA, using an
unsupervised clustering approach.
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in the cell cultures (Figure 2A). FACS analysis showed that all
analyzed cell cultures expressed CD56, thus confirming their
myogenic lineage, with no morphological differences between
cell groups (Figure 2B). However, the T2DM cultures analyzed
showed that a subpopulation of cells varied in their CD56
expression, suggesting that CD56 might be differently regulated
in the T2DM group (Supplementary Figure 1).
Single cells were then isolated using Fluidigm C1 IFC
microfluidic chips. Rates of capture for each chip and visual
scoring for each cell are summarized in Table 2. Subsequent
qPCR analysis showed that each miRNA was expressed in varying
fractions of cells ranging from 0 to 100% of cells but were
generally found to be comparable between healthy and T2DM
groups (Figure 3A). Interestingly, 5 miRNAs were detected in
notably differing percentages of cells between groups: miR-29b
was detected in ∼21% of T2DM cells but only in 5% of healthy
cells, whereas miR-106b was detected in 51% of healthy cells
versus 40% in the T2DM group (Figure 3A). Similarly, miR-143
and miR-145 from the miR-143/145 cluster were detected in 20%
of healthy cells versus 11% of T2DM, and 56 % of healthy cells
versus 43% of T2DM cells, respectively, whereas miR-138 was
detected in 66% of healthy cells versus 51% in the T2DM group.
Applying a principal component analysis (PCA), we observed
that miRNA expression profiles could be divided into 4 groups:
one cluster of miRNA expression profiles representing most of
the healthy cells had a near-complete overlap with a cluster
comprising the majority of T2DM cells (T2DM group 1),
suggesting that single-cell miRNA expression profiles are largely
similar between these groups (Figure 3B). Another separate
cluster (Mixed) contained cells from both groups, indicating
the presence of a subpopulation of cells with a distinct miRNA
expression profile not related to T2DM status (Figure 3B).
Finally, we observed a third cluster exclusively containing
T2DM cells (T2DM group 2) (Figure 3B), indicating that this
subpopulation, defined by a distinct miRNA expression profile,
is present in the T2DM group only. This subpopulation did not
include cells from subjects that were under medical treatment,
described in the method section (Human Subjects).
Applying PCA to the diabetes cells only, we found that
formation of the T2DM group 2 subpopulation was largely
driven by cells from a single donor, however, other cell donors
also contributed to a lesser degree (Supplementary Figure 2).
Interestingly, unsupervised clustering analysis revealed that miR-
29 family members miR-29a, miR-29b, and miR-29c were all
upregulated in the T2DM group 2 cell subpopulation (Figure 3C
and Table 3). Several miRNA transcriptional clusters were also
present within the T2DM group 2 subpopulation, including the
miR-193b/365 locus, the miR-199/214 locus, as well as miR-24
and miR-27b from the miR-23b/27b/24 locus, and miR-17 and
miR-19b from the miR-17 locus. Moreover, although the healthy
and T2DM groups largely overlapped, a number of miRNA
were also differentially regulated between these groups, namely,
miR-24, miR-29a, miR-17, and miR-145 (Figure 3C and Table 3).
To identify potential target genes of the differentially
expressed miRNA, we next applied a pathway prediction analysis
using the Diana miRPath tool (Vlachos et al., 2012). The pathway
prediction revealed that miRNAs differentially expressed between
the two diabetes cell clusters or between the healthy and T2DM
clusters were predicted to target several pathways, with the
ECM-receptor interaction in the KEGG pathway database being
the most likely to be targeted by either group of miRNAs
(Figures 4A,B). Interestingly, the PI3K/Akt pathway was also a
highly likely candidate pathway to be targeted by either group
of miRNAs (Figures 4A,B) The PI3K/Akt pathway is directly
regulated by insulin signaling (Boucher et al., 2014) and has
been shown to be dysregulated in skeletal muscle of people with
T2DM (Krook et al., 1998, 2000); we therefore chose to examine
which genes within this pathway would be targeted by the
differentially expressed miRNAs. miRNA-mRNA target analysis
of differentially expressed miRNA between the two diabetes
clusters showed that 53 genes within the PI3K/Akt pathway were
predicted targets of these miRNA and identified miR-29a, miR-
29b, and miR-29c as major regulatory nodes (Figure 4C). Three
of the four differentially expressed miRNA between the healthy
and T2DM group 1 clusters overlapped with the differentially
expressed miRNA between the two diabetes clusters, namely miR-
29a, miR-17, and miR-24, which were predicted to target 24
genes within the PI3K/Akt pathway; similarly, miR-29a showed
the highest degree of regulation of these miRNA (Figure 4D).
Interestingly, among the genes targeted by both subgroups of
miRNAs were genes previously described in T2DM, including
PTEN, IGF1, and VEGFA (Benjamin, 2001; Schneider et al., 2011;
Wu et al., 2011; Pal et al., 2012).
These data thus suggest that although most T2DM cells share
miRNA expression profiles with healthy cells, a subpopulation
of severely dysregulated muscle precursor cells reside within the
muscle progenitor T2DM cells (Figure 5).
DISCUSSION
While skeletal muscle plays a central role in the pathophysiology
of T2DM, the role of muscle precursor cells in counteracting
or maintaining a disease phenotype is poorly investigated. We
hypothesized that a sub-set of muscle precursor cells could
be severely dysregulated and were interested in the miRNAs,
which are potent regulators of cell differentiation, development,
and metabolism. To assess potential miRNA defined cellular
subpopulations, we performed miRNA profiling at a single cell
level on CD56+ human muscle precursor cells from healthy
subjects and individuals with T2DM.
We identified two sub-populations of muscle precursor cells
derived from healthy subjects. Interestingly, a distinct third
sub-population was detected in cells from people with T2DM.
This T2DM-specific subpopulation was characterized by a high
expression of miR-29, previously reported as upregulated in
T2DM in muscle (Massart et al., 2017). Moreover, miR-29b was
detected in 21% of the cells derived from subjects with T2DM
compared to only 5% of the cells derived from healthy subjects,
further emphasizing the disease-association of mir-29 in the
muscle precursor cells.
The advantage of performing single cell analysis becomes clear
when comparing our current data with a recent study where
we identified miR-23b and miR-27b as downregulated in muscle
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FIGURE 4 | (A,B): miRNA target pathway predictions were performed using Diana miRPath software (Vlachos et al., 2012). Pathway predictions for differentially
expressed miRNA between T2DM group 1 and T2DM group 2 clusters are shown in (A); pathway predictions for differentially expressed miRNA between Healthy
and T2DM group 1 clusters are shown in (B). Visualization of miRNA-gene interactions were performed using the CytoScape app CyTargetLinker (Shannon et al.,
2003; Kutmon et al., 2013). Interactions for differentially expressed miRNA between T2DM group 1 and T2DM group 2 clusters with genes within the PI3K/Akt
signaling pathway are shown in (C); interactions for differentially expressed miRNA between Healthy and T2DM clusters with genes within the PI3K/Akt signaling
pathway are shown in (D). miRNA node size indicates number of interactions with target genes.
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FIGURE 5 | Schematic summary of key findings of the present study. In a previous study using bulk miRNA analysis, a limited number of differentially expressed
miRNA were identified in isolated T2DM muscle precursor cells. The present study examined the single-cell expression of miRNA and found that a subgroup of
T2DM muscle precursor cells had a distinct miRNA expression profile.
precursor cells and in vitro differentiated myotubes derived from
people with T2DM (Henriksen et al., 2017). In our previous
study, miR-24, which is transcribed from the same locus as miR-
23b and miR-27b, was not identified as differentially expressed
in the microarray analysis. Recent advances in single-cell-based
analyses have made it increasingly clear that stem cell populations
are not homogenous entities (Kumar et al., 2014; Wilson et al.,
2015). We therefore hypothesized that subpopulations of T2DM
muscle stem cells would have miRNA expression profiles distinct
from healthy cells, and that measuring the miRNA expression in
“bulk samples” might mask underlying subpopulation trends.
Indeed, in the current study, using a single-cell approach
we identified miR-24 as the most distinctly regulated miRNA
between muscle precursor cells from healthy donors compared
to T2DM donors. However, miR-24 was upregulated in the
T2DM specific subpopulation while being downregulated in the
T2DM population that mostly overlapped with cells from healthy
donors/subjects. Thus, the data presented here demonstrates
that two subpopulations of T2DM muscle cells express miR-24
to a highly different degree and measuring an average miR-
24 expression of these two populations might therefore yield a
result that represents neither subgroup, which could explain why
miR-24 was not found to be significantly downregulated in our
previous study (Altschuler and Wu, 2010; Henriksen et al., 2017).
Although the applied single-cell approach has its clear
advantages in terms of highlighting cellular heterogeneity,
there are certain drawbacks of this method to consider when
interpreting the data. A specific aim of the present study
was to investigate the single-cell expression of a group of
previously described miRNA (Henriksen et al., 2017). However,
the commercially available pool of primers we used for miRNA
pre-amplification did not cover all these miRNAs, and we were
thus only able to measure the single-cell expression of some of
the previously identified miRNA. Functional implications of our
findings in terms of which specific miRNA that are differentially
regulated in T2DM cells might therefore be difficult to conclude.
Moreover, the minuscule amounts of cellular material present
when working with single cells might be below the detection
limit of the primer assays we used (Stahlberg et al., 2013).
For example, we previously found miR-23b to be one of the
most differentially regulated miRNA between healthy and T2DM
groups over time (Henriksen et al., 2017), whereas in this study
miR-23b expression was only detected in a small fraction of cells
(data not shown). This discrepancy might be a technical issue
due to failure of our primer assays to bind to the small amount
of miRNA present. A final issue to consider is that the data
presented here was not normalized to an endogenous control
miRNA. Instead, we made the assumption that the single cell
input would serve as a basis for normalization. Normalizing
on a per-cell basis has been described as a superior method
for normalization in single-cell studies to using an endogenous
reference gene (Stahlberg et al., 2013), however, the optimal
normalization approach can be debated.
One issue to consider in the present study is that all donors
included in the study were not represented in the T2DM group
2 subcluster. Rather, the T2DM group 2 cells came from 3 out of
the 5 diabetic donors with most cells being from one individual
donor, thus the observed heterogeneity in miRNA expression
may also vary between cell donors. Nevertheless, as capture rates
also varied considerably between each IFC chip (Table 2), we may
have failed to isolate cells belonging to the T2DM group 2 cluster
due to a low overall capture rate in cells from these donors.
The most striking biological finding in the current study
was the identification of a miRNA-defined T2DM-specific
subpopulation of muscle precursor cells along with a T2DM-
dependent dysregulation of three members of the miR-29 family:
miR-29a, miR-29b, and miR-29c. These miRNAs are transcribed
from two different genomic loci but possess the same seeding
sequence, and are thus predicted to target the same mRNA
molecules. These findings are interesting to interpret in light of a
previously performed meta-analysis of tissue miRNA expression
in models of diabetes, identifying miR-29 as the most upregulated
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miRNA across different insulin-responsive tissues (Zhu and
Leung, 2015). Furthermore, Massart et al. (2017) recently showed
that miR-29a and miR-29c were increased in skeletal muscle
tissue from patients with T2DM and regulated insulin-mediated
glucose metabolism, and miR-29b has similarly been shown
to be increased in T2DM muscle (He et al., 2007; Gerlinger-
Romero et al., 2017). Thus, there is strong evidence in the
literature for an association between T2DM and increased miR-
29 expression.
We found that miR-29a, miR-29b, and miR-29c were all
upregulated in the T2DM-specific subpopulation, consistent with
the previous literature on miR-29 expression being increased
in T2DM. Moreover, two other miRNAs were found to be
differentially expressed either between the healthy and T2DM
group 1 clusters or the two diabetes clusters, namely miR-17 and
miR-24. Both of these miRNA have been shown to be regulated
by glucose levels (Xiang et al., 2015; Dong et al., 2016) and
their concentrations are increased in patients with T2DM (Villard
et al., 2015); thus, these two miRNA may represent novel markers
of T2DM in skeletal muscle. Interestingly, we demonstrate that
these changes are manifested already in muscle precursor cells
and are specifically accumulated in a subset of cells, suggesting
that muscle precursor cells are affected by and/or contribute to
the T2DM muscle phenotype to varying degrees.
Another interesting finding was that although most miRNA
were expressed in comparable fractions of cells between groups,
miR-29b was only detected in 5% of the muscle precursor cells
from healthy individuals, whereas 21% of the muscle precursor
cells derived from people with type 2 diabetes were expressing
this miRNA, further supporting a role of miR-29 in T2DM
disease phenotype, as well as the establishment of T2DM at
muscle precursor cell level. Some of the other miRNAs including
miR-106b, miR-138, miR-143, and miR-145 were modestly less
detected in the cells derived from people with T2DM compared
to healthy controls. Although these differences could be technical
and therefore should not be over interpreted, these miRNAs have
also all been described to be regulated in model systems of muscle
insulin resistance or T2DM (Blumensatt et al., 2013, 2014; Zhang
et al., 2013; Riches et al., 2014) or glucose uptake and insulin
sensitivity (Jordan et al., 2011; Zhou et al., 2016), suggesting a
functional relevance of this finding.
Finally, in addition to the T2DM-specific sub-population,
we identified another separate cluster of cells comprising a
mixture of healthy and T2DM cells. Given that our muscle
precursor cells were sorted for CD56 positivity, these cells might
represent a subtype of muscle precursor cells common to both
groups. However, we cannot exclude the possibility that this
cluster is due to presence of a non-muscle cell type, such
as fibroblasts. Interestingly, it was recently demonstrated that
fibroblasts contribute support during myogenic differentiation
(Mackey et al., 2017) bringing this cell population also to interest
when comparing isolated cells from healthy subjects and subjects
with T2DM.
CONCLUSION
We here show that muscle precursor cells derived from humans
with T2DM have subpopulations with distinct miRNA expression
profiles. These data indicate that that only a subgroup of
T2DM muscle precursor cells differ in expression of diabetes-
associated miRNA, which may reflect a heterogeneous disease
phenotype in T2DM muscle cells. The data presented here thus
provides a novel conceptual basis for understanding the muscular
phenotype of T2DM.
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